As the US is pushing for a vaccine booster drive to fight the delta variant of COVID-19, the ability to mix one manufacturer’s vaccine with another is an open question.New government research from National Institute of Health (NIH) suggests that the answer may be yes.
NS NIH research What was announced on Wednesday discovered that it may be possible for patients to “mix” the vaccine, regardless of the vaccine they originally received. The study involved 458 volunteers grouped based on the first vaccine received between Pfizer-BioNTech, Johnson & Johnson, or Moderna.
Volunteers received boosters from the manufacturer that differed from the original dose and monitored how the number of antibodies in the body changed. Two and four weeks after receiving the booster, it was found that the recipients of the shots from the second manufacturer usually had more antibodies than the recipients who received the booster from the original source. ..
For example, patients vaccinated with Johnson & Johnson showed five times the amount of antibody in the system after receiving booster immunity. However, patients who received boost immunization from Pfizer or Moderna in addition to the Johnson & Johnson vaccine showed even higher levels of antibody than if the system had only one vaccine type.
These results will arrive prior to the decision of the Food and Drug Administration (FDA) Advisory Board, which will arrive on Friday. FDA is now Measurement Whether to grant an emergency permit to allow boosters from Moderna and Johnson & Johnson. Pfizer’s vaccine is the only vaccine approved for booster shots in the United States so far.
NS Centers for Disease Control and Prevention (CDC) We are also currently reviewing Moderna and Johnson & Johnson vaccine booster applications.
If they receive a go-ahead from the FDA, it could benefit President Joe Biden’s booster vaccination drive. The original plan enacted on September 20 was Shrink Only for people over the age of 65 and those with existing health problems.The plan went on Pfizer only Boosters available after regulators warn Moderna that there is not enough data to proceed with it.
Because of all its benefits, NIH studies alone are unlikely to upset the FDA to immediately approve vaccine mixing and matching. This study has not been peer-reviewed and its authors have found that their sample size spans the United States across age ranges or race and ethnic groups to measure how boosters work for everyone. It states that it does not fully represent the population of.
“The sample size is not sufficient for comparison between groups, and the demographics of the people studied are not representative of the US population,” the study author writes.
NIH Study Suggests A ‘Mix And Match’ Of COVID-19 Vaccines Could Be Effective Source link NIH Study Suggests A ‘Mix And Match’ Of COVID-19 Vaccines Could Be Effective